The largest clinical trial ever conducted amongst people with type 2 diabetes has been completed. A global study, ADVANCE (Action in Diabetes and Vascular Disease) ran over a five year period and investigated blood glucose lowering on microvascular and macrovascular events.
The trial had 11,000 participants from over 20 countries, and the results will be presented at the American Diabetes Association Scientific Sessions coming up in June.
ADVANCE principal investigator Professor John Chalmers reportedly commented: ” People with diabetes have a two to four-fold greater risk of experiencing a cardiovascular event compared to non-diabetics . However, despite this high risk, there is surprisingly little evidence about the role of intensive blood glucose control in the prevention of diabetic vascular diseases.”
Study Director Associate Professor Anushka Patel was reported as commenting: “ADVANCE will provide new and robust evidence on whether intensive glucose lowering treatment improves outcomes and could have huge implications for the practical management of type 2 diabetes worldwide.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…